Cardiovascular cell therapy - MG Biotherapeutics

Drug Profile

Cardiovascular cell therapy - MG Biotherapeutics

Alternative Names: Adult stem cell therapy-heart failure - MG Biotherapeutics; Ventricular restoration cell therapy - MG Biotherapeutics

Latest Information Update: 27 Sep 2007

Price : $50

At a glance

  • Originator MG-Biotherapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Heart failure; Ischaemic heart disorders

Most Recent Events

  • 27 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Ischaemic heart disorders pharmacodynamics section
  • 28 Apr 2006 Preclinical trials in Heart failure in France (unspecified route)
  • 27 Feb 2006 Genzyme has halted the enrolment of new patients in its phase II (MAGIC) trial for Ischaemic heat disorders in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top